A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
BeOne Medicines
Royal Marsden NHS Foundation Trust
Incyte Corporation
Canadian Cancer Trials Group
Pfizer
Canadian Cancer Trials Group
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Hoffmann-La Roche
Boundless Bio, Inc.
Novartis
AstraZeneca
LeonaBio
Hoffmann-La Roche
Novartis
Laekna Limited
Novartis
Relay Therapeutics, Inc.
Incyclix Bio
InventisBio Co., Ltd
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Canadian Cancer Trials Group
AstraZeneca
Novartis
TransThera Sciences (Nanjing), Inc.
Merck Sharp & Dohme LLC
Terremoto Biosciences Inc.
Hoffmann-La Roche
Ellipses Pharma
Eli Lilly and Company
AstraZeneca
Pfizer
Hoffmann-La Roche
Ensem Therapeutics
Atavistik Bio, Inc
Hoffmann-La Roche
Olema Pharmaceuticals, Inc.
Aminex Therapeutics, Inc.
Genentech, Inc.
Eisai Inc.
University of California, Irvine
BeOne Medicines
Dana-Farber Cancer Institute
Eli Lilly and Company
Mayo Clinic
City of Hope Medical Center
Novartis
Pfizer
Alliance Foundation Trials, LLC.